Cargando…

Medical treatment for urogenital tuberculosis (UGTB)

Urogenital tuberculosis (UGTB) should in general be treated as pulmonary TB with a four-drug regimen of Isoniazid, Rifampicin, Ethambutol and Pyrazinamide for a total of 6 months, Ethambutol and Pyrazinamide only the first two months. Some patients may need longer treatment (cavitary disease, kidney...

Descripción completa

Detalles Bibliográficos
Autor principal: Wejse, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: German Medical Science GMS Publishing House 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301712/
https://www.ncbi.nlm.nih.gov/pubmed/30671335
http://dx.doi.org/10.3205/id000039
_version_ 1783381848916754432
author Wejse, Christian
author_facet Wejse, Christian
author_sort Wejse, Christian
collection PubMed
description Urogenital tuberculosis (UGTB) should in general be treated as pulmonary TB with a four-drug regimen of Isoniazid, Rifampicin, Ethambutol and Pyrazinamide for a total of 6 months, Ethambutol and Pyrazinamide only the first two months. Some patients may need longer treatment (cavitary disease, kidney abscess/malfunction, HIV co-infection). Treatment of multi-drug resistant tuberculosis (MDR-TB) requires use of long-term intravenous treatment with aminoglycosides and other drugs with considerable toxicity for 18–24 months. Complications such as urinary tract obstruction may occur and should be treated with corticosteroids or surgery.
format Online
Article
Text
id pubmed-6301712
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher German Medical Science GMS Publishing House
record_format MEDLINE/PubMed
spelling pubmed-63017122019-01-22 Medical treatment for urogenital tuberculosis (UGTB) Wejse, Christian GMS Infect Dis Article Urogenital tuberculosis (UGTB) should in general be treated as pulmonary TB with a four-drug regimen of Isoniazid, Rifampicin, Ethambutol and Pyrazinamide for a total of 6 months, Ethambutol and Pyrazinamide only the first two months. Some patients may need longer treatment (cavitary disease, kidney abscess/malfunction, HIV co-infection). Treatment of multi-drug resistant tuberculosis (MDR-TB) requires use of long-term intravenous treatment with aminoglycosides and other drugs with considerable toxicity for 18–24 months. Complications such as urinary tract obstruction may occur and should be treated with corticosteroids or surgery. German Medical Science GMS Publishing House 2018-08-09 /pmc/articles/PMC6301712/ /pubmed/30671335 http://dx.doi.org/10.3205/id000039 Text en Copyright © 2018 Wejse This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Wejse, Christian
Medical treatment for urogenital tuberculosis (UGTB)
title Medical treatment for urogenital tuberculosis (UGTB)
title_full Medical treatment for urogenital tuberculosis (UGTB)
title_fullStr Medical treatment for urogenital tuberculosis (UGTB)
title_full_unstemmed Medical treatment for urogenital tuberculosis (UGTB)
title_short Medical treatment for urogenital tuberculosis (UGTB)
title_sort medical treatment for urogenital tuberculosis (ugtb)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301712/
https://www.ncbi.nlm.nih.gov/pubmed/30671335
http://dx.doi.org/10.3205/id000039
work_keys_str_mv AT wejsechristian medicaltreatmentforurogenitaltuberculosisugtb